ABCL
NEUTRAL
$3.49
Live
AbCellera Biologics Inc. · NASDAQ
Target $9.17
(+162.7%)
$1.89
52W Range
$6.51
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Mar 14, 2026
Market cap
$1.06B
P/E
N/A
ROE
-14.5%
Profit margin
-194.9%
Debt/Equity
0.15
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
72%
ABCL exhibits severe financial distress according to the Piotroski F-Score (1/9), indicating weak operational and financial health. The Altman Z-Score is unavailable, but the company's negative profitability metrics—particularly a -194.88% profit margin and -14.47% ROE—highlight deep operational inefficiencies. Despite a 788.2% YoY revenue growth and strong earnings surprise history (average +30.86% over last 4 quarters), the company remains unprofitable and carries significant valuation risk. The current price of $3.49 trades at a steep 14.08 Price/Sales ratio, far exceeding sector averages, suggesting speculative pricing. Analysts' target price of $9.17 implies strong upside potential, but this is based on unproven profitability and high risk.
Key Strengths
Exceptional 788.2% YoY revenue growth, signaling strong market traction
Positive earnings surprise history (average +30.86% over last 4 quarters)
Strong recent Q/Q EPS growth (+84.2%) and year-over-year EPS improvement (+75.0%)
Low debt/equity ratio (0.15) and high liquidity (current ratio 11.32, quick ratio 10.07)
Insider sentiment at 60/100, indicating moderate confidence in long-term prospects
Key Risks
Piotroski F-Score of 1/9 indicates severe financial and operational weakness
Negative profit, operating, and gross margins across all metrics (-194.88%, -63.72%, -148.68%)
No Graham Number or intrinsic value estimate due to lack of profitability and negative earnings
Forward P/E of -4.53 and negative earnings imply no current profitability
High Price/Sales (14.08) and lack of cash flow metrics suggest overvaluation relative to fundamentals
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
37
Weak
40
75
50
20
0
AI Verdict
Cautionary Buy
Key drivers: High revenue growth and positive earnings surprises, Strong liquidity and low leverage, Negative profitability and weak Piotroski score, Speculative valuation with no earnings support, Analyst price target implies significant upside
Confidence
75%
Value
40/100
Ref P/E, PEG, Graham Number
Positives
- Low debt/equity (0.15) and strong current/quick ratios
- High market cap ($1.06B) with strong growth potential
Watchpoints
- Price/Sales of 14.08 is extremely high for a loss-making company
- No Graham Number or intrinsic value due to negative earnings
- Forward P/E of -4.53 invalidates traditional valuation models
Future
75/100
Ref Growth rates
Positives
- 788.2% YoY revenue growth indicates explosive top-line expansion
- Recent earnings surprises show improving execution and forecasting accuracy
- Q/Q EPS growth of +84.2% suggests accelerating profitability momentum
Watchpoints
- No current profitability or positive cash flow to sustain growth
- High growth is not yet translating into earnings or margins
- Unproven path to sustainable profitability
Past
50/100
Ref Historical trends
Positives
- Consistent earnings beat rate (2/4 in last 4 quarters)
- Average earnings surprise of +30.86% over last 4 quarters
- Improving EPS trend from -0.16 to -0.03 in recent quarters
Watchpoints
- Historical earnings volatility with large negative surprises (e.g., -900% in 2023-02-21)
- Frequent losses and inconsistent profitability
- Negative ROE and ROA across multiple years
Health
20/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Low debt/equity ratio (0.15)
- Extremely high current and quick ratios (11.32, 10.07)
Watchpoints
- Piotroski F-Score of 1/9 indicates severe financial distress
- Negative ROE (-14.47%), ROA (-9.99%), and ROIC (N/A)
- No Altman Z-Score available, but negative profitability and high leverage risk
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- Dividend strength of 0/100
- Unlikely to pay dividends given current losses and reinvestment needs
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$3.49
Analyst Target
$9.17
Upside/Downside
+162.7%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ABCL and closest competitors.
Updated 2026-03-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ABCL
AbCellera Biologics Inc.
Primary
|
-90.7% | -53.9% | +45.4% | -21.9% | +11.5% | +1.2% |
|
PNTG
The Pennant Group, Inc.
Peer
|
-26.0% | +129.2% | +16.1% | +27.2% | -7.9% | -4.0% |
|
AKTS
Aktis Oncology, Inc.
Peer
|
-15.2% | -15.2% | -15.2% | -15.2% | +5.2% | +1.0% |
|
KMTS
Kestra Medical Technologies, Ltd.
Peer
|
-18.2% | -18.2% | -26.2% | -18.8% | -19.3% | -9.9% |
|
NEO
NeoGenomics, Inc.
Peer
|
-83.1% | -45.5% | -14.1% | -11.0% | +1.3% | +3.6% |
ABC
AbCellera Biologics Inc.
Primary
5Y
-90.7%
3Y
-53.9%
1Y
+45.4%
6M
-21.9%
1M
+11.5%
1W
+1.2%
PNT
The Pennant Group, Inc.
Peer
5Y
-26.0%
3Y
+129.2%
1Y
+16.1%
6M
+27.2%
1M
-7.9%
1W
-4.0%
AKT
Aktis Oncology, Inc.
Peer
5Y
-15.2%
3Y
-15.2%
1Y
-15.2%
6M
-15.2%
1M
+5.2%
1W
+1.0%
KMT
Kestra Medical Technologies, Ltd.
Peer
5Y
-18.2%
3Y
-18.2%
1Y
-26.2%
6M
-18.8%
1M
-19.3%
1W
-9.9%
NEO
NeoGenomics, Inc.
Peer
5Y
-83.1%
3Y
-45.5%
1Y
-14.1%
6M
-11.0%
1M
+1.3%
1W
+3.6%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-4.53
PEG Ratio
N/A
P/B Ratio
1.08
P/S Ratio
14.08
EV/Revenue
8.88
EV/EBITDA
-3.42
Market Cap
$1.06B
Profitability
Profit margins and return metrics
Profit Margin
-194.88%
Operating Margin
-63.72%
Gross Margin
-148.68%
ROE
-14.47%
ROA
-9.99%
Growth
Revenue and earnings growth rates
Revenue Growth
+788.2%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.15
Low debt
Current Ratio
11.32
Strong
Quick Ratio
10.07
Excellent
Cash/Share
$1.76
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-07
$N/A
2026-02-24
$-0.03
+83.3% surprise
2025-11-06
$-0.19
-17.3% surprise
2025-08-07
$-0.12
+26.5% surprise
Healthcare Sector Comparison
Comparing ABCL against 393 companies in the Healthcare sector
(24 bullish, 129 neutral, 240 bearish)
Return on Equity (ROE)
-14.47%
This Stock
vs
-101.52%
Sector Avg
-85.7%
(Below Avg)
Profit Margin
-194.88%
This Stock
vs
-12.47%
Sector Avg
+1462.9%
(Superior)
Debt to Equity
0.15
This Stock
vs
3.4
Sector Avg
-95.6%
(Less Debt)
Revenue Growth
788.2%
This Stock
vs
124.21%
Sector Avg
+534.6%
(Fast Growth)
Current Ratio
11.32
This Stock
vs
4.56
Sector Avg
+148.4%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ABCL
AbCellera Biologics Inc.
|
NEUTRAL | $1.06B | - | -14.5% | -194.9% | $3.49 | |
|
PNTG
The Pennant Group, Inc.
|
BULLISH | $1.06B | 36.21 | 9.8% | 3.1% | $30.42 | Compare |
|
AKTS
Aktis Oncology, Inc.
|
BEARISH | $1.05B | - | -26.5% | -% | $18.99 | Compare |
|
KMTS
Kestra Medical Technologies, Ltd.
|
BEARISH | $1.04B | - | -92.7% | -173.0% | $17.87 | Compare |
|
NEO
NeoGenomics, Inc.
|
NEUTRAL | $1.09B | - | -12.4% | -14.9% | $8.35 | Compare |
ABCL
AbCellera Biologics Inc.
NEUTRAL
Mkt Cap
$1.1B
P/E
-
ROE
-14.5%
Price
$3.49
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-27 | THERMOPYLAE HOLDINGS, LTD. | Beneficial Owner of more than 10% of a Class of Security | Purchase | 38,000 | $130,720 |
| 2026-02-27 | BOOTH ANDREW | Chief Financial Officer | Purchase | 42,600 | $145,692 |
| 2026-02-26 | THERMOPYLAE HOLDINGS, LTD. | Beneficial Owner of more than 10% of a Class of Security | Purchase | 177,457 | $580,284 |
| 2025-12-18 | THERMOPYLAE HOLDINGS, LTD. | Beneficial Owner of more than 10% of a Class of Security | Gift | 225,000 | - |
| 2025-11-26 | MONTALBANO JOHN S. | Director | Purchase | 50,000 | $178,460 |
THERMOPYLAE HOLDINGS, LTD.
Beneficial Owner of more than 10% of a Class of Security
2026-02-27
38,000 shares
·
$130,720
BOOTH ANDREW
Chief Financial Officer
2026-02-27
42,600 shares
·
$145,692
THERMOPYLAE HOLDINGS, LTD.
Beneficial Owner of more than 10% of a Class of Security
2026-02-26
177,457 shares
·
$580,284
THERMOPYLAE HOLDINGS, LTD.
Beneficial Owner of more than 10% of a Class of Security
2025-12-18
225,000 shares
MONTALBANO JOHN S.
Director
2025-11-26
50,000 shares
·
$178,460
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
6 analysts
Leerink Partners
2025-11-07
Outperform
Market Perform
Past News Coverage
Recent headlines mentioning ABCL from our newsroom.
Newest → oldest
No matching news yet.